Ellipsis Neurotherapeutics, Inc.

Neurotherapeutics company raises CDN$6 million in series A financing

Published in Drug Law Weekly, December 7th, 2004

Ellipsis Neurotherapeutics, Inc., (ENI), a Toronto (Ontario, Canada)-based privately held biotechnology company, announced that it had secured CDN$6 million for the preclinical and clinical development of the company's lead compounds for the treatment of Alzheimer disease (AD).

The financing was led by Newport Partners and involved a syndicate of private and institutional investors, including the Canadian Medical Discoveries Fund.

The transaction also included an investment by Transition Therapeutics, Inc., a Canadian biotech company. Along with Transition's investment, ENI will also have access to the drug-development, intellectual property, and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2004-12-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry